{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/designing-optimal-long-term-follow-program-gene-therapies-and-genetically-modified-cell#webpage",
"url": "https://www.fortrea.com/insights/designing-optimal-long-term-follow-program-gene-therapies-and-genetically-modified-cell",
"name": "Designing an optimal long-term follow- up program for gene therapies and genetically modified cell therapies",
"description": "This Fortrea white paper explores clinical development programs affecting gene therapies and genetically modified cell therapies across advanced therapy research settings. The content focuses on gene therapies and genetically modified cell therapies, advanced therapy planning, manufacturing coordination, clinical development programs, and research strategies associated with therapy development. The white paper highlights factors related to manufacturing processes, therapy development planning, clinical study preparation, operational coordination, and research approaches affecting advanced therapy programs. Fortrea discusses scientific and development perspectives designed to support therapy planning, strengthen coordination across development activities, and improve research approaches associated with gene therapies and genetically modified cell therapies. By integrating advanced therapy planning with manufacturing coordination and clinical development strategies, the white paper provides insights into clinical development programs affecting gene therapies and genetically modified cell therapies across evolving advanced therapy research environments."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Designing an optimal long-term follow- up program for gene therapies and genetically modified cell therapies",
"item": "https://www.fortrea.com/insights/designing-optimal-long-term-follow-program-gene-therapies-and-genetically-modified-cell"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/designing-optimal-long-term-follow-program-gene-therapies-and-genetically-modified-cell#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/designing-optimal-long-term-follow-program-gene-therapies-and-genetically-modified-cell#webpage"
},
"headline": "Designing an optimal long-term follow- up program for gene therapies and genetically modified cell therapies",
"description": "This Fortrea white paper explores clinical development programs affecting gene therapies and genetically modified cell therapies across advanced therapy research settings. The content focuses on gene therapies and genetically modified cell therapies, advanced therapy planning, manufacturing coordination, clinical development programs, and research strategies associated with therapy development. The white paper highlights factors related to manufacturing processes, therapy development planning, clinical study preparation, operational coordination, and research approaches affecting advanced therapy programs. Fortrea discusses scientific and development perspectives designed to support therapy planning, strengthen coordination across development activities, and improve research approaches associated with gene therapies and genetically modified cell therapies. By integrating advanced therapy planning with manufacturing coordination and clinical development strategies, the white paper provides insights into clinical development programs affecting gene therapies and genetically modified cell therapies across evolving advanced therapy research environments.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-02/program-for-gene-therapies-and-genetically-modified-cell-therapies.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-02-04",
"dateModified": "2025-02-04",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-02/program-for-gene-therapies-and-genetically-modified-cell-therapies.pdf",
"encodingFormat": "application/pdf"
}
}
]
}